November 27, 2024 5:02 PM

Failure of AstraZeneca’s opioid drug trial a major blow for addiction medications: report

The failure of AstraZeneca’s AZD4041 drug trial to combat opioid use disorder (OUD) highlights the challenges in developing non-opioid medications for addiction and withdrawal, according to a report on Wednesday. OUD is a chronic neurological disorder that causes compulsive, repeated use of opioid drugs, leading to prolonged self-administration. The company recently terminated the development of AZD4041 during a Phase II trial, as the orexin 1 receptor antagonist showed a drug-drug interacti...